Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus taeda pollen extract is a non-standardized allergenic extract derived from the pollen of the Loblolly Pine (*Pinus taeda*). Developed and manufactured by Greer Laboratories, it is primarily utilized as a diagnostic tool to identify allergic sensitivities in patients suspected of having pollen-related respiratory conditions. The extract is administered via percutaneous (scratch/prick) or intradermal testing, where it works by cross-linking allergen-specific IgE antibodies on the surface of mast cells and basophils in sensitized individuals. This interaction triggers the release of histamine and other mediators, resulting in a visible wheal-and-flare reaction. While primarily diagnostic, such extracts can also be used in subcutaneous immunotherapy (SCIT) to induce immunological tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus taeda pollen extract.